Elixirgen Scientific, through its parent company, Elixirgen, LLC, has entered into a license agreement with ID Pharma Co., Ltd., a wholly owned subsidiary of the I’Rom Group (TYO: 2372) for Sendai Virus Vector technology. This technology enables Elixirgen Scientific to add specific genes to Sendai Virus Vectors (SeV) and to manufacture and sell related products for research purposes. The deal will enhance Elixirgen Scientific’s own product portfolio – Sendai Virus has special characteristics that can improve the Quick-Tissue™ series’ properties. Elixirgen Scientific will be looking to release Quick-Tissue™ series kits incorporating Sendai Virus Technology by end of Q2 2017.

Link to I’Rom Group press release (only in Japanese)